DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Bioequivalence Study of Aciclovir 5% Cream in Japanese Healthy Volunteers

Information source: GlaxoSmithKline
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Herpes Labialis

Intervention: New formulation (Drug); Current formulation (Drug)

Phase: Phase 1

Status: Completed

Sponsored by: GlaxoSmithKline

Official(s) and/or principal investigator(s):
GSK Clinical Trials, Study Director, Affiliation: GlaxoSmithKline


This study is designed to show bioequivalence between Current and New formulation of Aciclovir cream 5% in keratin layer of the epidermis in Japanese Subjects

Clinical Details

Official title: Bioequivalence Study of Aciclovir 5% Cream - Bioequivalence Study of Aciclovir Cream Between Current and New Formulation in Japanese Healthy Volunteers -

Study design: Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Bioequivalence of Aciclovir amount in keratin layer of the epidermis between Current and New formulation of Aciclovir cream

Secondary outcome: To investigate the safety and tolerability of New and Current formulation of Aciclovir Cream 5% following single topical application in healthy Japanese male subjects


Minimum age: 20 Years. Maximum age: 55 Years. Gender(s): Male.


Inclusion Criteria:

- Healthy Japanese adult males between 20 and 55 years of age, inclusive.

Healthy subjects are defined as individuals who are free from clinically significant disease as determined by their medical history, physical examination, clinical laboratory examinations, vital sign, 12-lead ECG, immunology tests and urinary drug screen test.

- Bodyweight >50 kg and body mass index (BMI) between 18. 5 and 28. 0 at screening.

- Subjects must be capable of providing written informed consent, which includes

compliance with the requirements and restrictions listed in the consent form.

- Baseline QTc interval <450 msec.

- Non-smoker or ex-smoker having ceased smoking for at least 6 months.

- Clinical laboratory examination (AST, ALT, ALP and GGT) at screening are within the

normal range.

- The subject is able to attend all visits and complete the study.

Exclusion Criteria:

- Any clinically relevant abnormality identified on the screening physical examination,

vital sign measurement, 12-lead ECG recording and/or clinical laboratory examination that is deemed by the principal investigator and/or medical monitor to make the subject ineligible for inclusion because of a safety concern.

- History of regular alcohol consumption exceeding, on average, 14 drinks/week (1 drink

= 5 ounces (150 mL) of wine or 350 mL of beer or 1. 5 ounces (45 mL) of 80 proof distilled spirits) within 6 months of screening.

- Positive for urine drug at screening.

- Positive for syphilis, HIV antibody, Hepatitis B surface antigen, Hepatitis C

antibody or HTLV-1 antibody at screening.

- Donation of blood in excess of 400mL within 4 months or 200mL within 1 months prior

to at screening.

- History of drug abuse, or current conditions of drug abuse or alcoholism.

- Participation in a clinical study or post-marketing study with an investigational or

a non-investigational product or device within 4 months of preceding the first application of study medication.

- Participation in another clinical study or post-marketing study in which the subject

is or will be exposed to an investigational or a non-investigational product or device.

- History of asthma, anaphylaxis or anaphylactoid reactions, severe allergic responses.

- The subject has an allergy for any drug or idiosyncrasy. This excludes a pollen

allergy without current symptoms.

- At the part obtaining keratinized layer, having exanthem, pigment abnormality, the

skin symptoms such as wounds and/or an excessive sunburn.

- History of clinically significant itching, erythema and/or rash by any paster.

Locations and Contacts

GSK Investigational Site, Tokyo 160-0017, Japan
Additional Information

Starting date: April 2008
Last updated: March 21, 2013

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017